Literature DB >> 18647251

Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations.

Alexander Göhler1, Benjamin P Geisler, Jennifer M Manne, Mikhail Kosiborod, Zefeng Zhang, William S Weintraub, John A Spertus, G Scott Gazelle, Uwe Siebert, David J Cohen.   

Abstract

OBJECTIVES: For economic evaluations of chronic heart failure (CHF) management strategies, utilities are not currently available for disease proxies commonly used in Markov models. Our objective was to estimate utilities for New York Heart Association (NYHA) classification and number of cardiovascular rehospitalizations.
METHODS: EuroQol 5D data from the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study trial were used to estimate utilities as a function of NYHA classification and number of cardiovascular rehospitalizations.
RESULTS: In multivariate regression analyses adjusted for age (60 years), female sex and absence of further comorbidities, utilities for NYHA classes I-IV were 0.90, 0.83, 0.74, and 0.60 (P-value < 0.001 for trend). For cardiovascular rehospitalizations 0, 1, 2 and >or=3, the associated utilities were 0.88, 0.85, 0.84, and 0.82 (P-value < 0.001 for trend).
CONCLUSIONS: NYHA class and number of cardiovascular rehospitalizations are established proxies for CHF progression and can be linked to utilities when used as health states in a Markov model. NYHA class should be used when feasible.

Entities:  

Mesh:

Year:  2008        PMID: 18647251     DOI: 10.1111/j.1524-4733.2008.00425.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  36 in total

1.  Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.

Authors:  Nimer Alkhatib; Nancy K Sweitzer; Christopher S Lee; Brian Erstad; Marion Slack; Mahdi Gharaibeh; Jason Karnes; Walter Klimecki; Kenneth Ramos; Ivo Abraham
Journal:  Am J Cardiovasc Drugs       Date:  2021-03       Impact factor: 3.571

2.  Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects.

Authors:  Jennifer M Yeh; Anju Nohria; Lisa Diller
Journal:  Ann Intern Med       Date:  2014-05-20       Impact factor: 25.391

3.  Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System.

Authors:  Jordana K Schmier; Kevin L Ong; Gregg C Fonarow
Journal:  Clin Cardiol       Date:  2017-03-08       Impact factor: 2.882

4.  Association Between Medicare Hospital Readmission Penalties and 30-Day Combined Excess Readmission and Mortality.

Authors:  Ahmad A Abdul-Aziz; Rodney A Hayward; Keith D Aaronson; Scott L Hummel
Journal:  JAMA Cardiol       Date:  2017-02-01       Impact factor: 14.676

5.  The use of economic evaluation in CAM: an introductory framework.

Authors:  Emily Ford; Daniela Solomon; Jon Adams; Nicholas Graves
Journal:  BMC Complement Altern Med       Date:  2010-11-11       Impact factor: 3.659

6.  Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant.

Authors:  Brian Wayda; Alexander T Sandhu; Justin Parizo; Jeffrey J Teuteberg; Kiran K Khush
Journal:  J Heart Lung Transplant       Date:  2021-09-13       Impact factor: 10.247

Review 7.  Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B).

Authors:  S Sehatzadeh; B Doble; F Xie; G Blackhouse; K Campbell; K Kaulback; K Chandra; R Goeree
Journal:  Ont Health Technol Assess Ser       Date:  2012-05-01

8.  Cost-Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy.

Authors:  Defne A Magnetta; JaHyun Kang; Peter D Wearden; Kenneth J Smith; Brian Feingold
Journal:  Pediatr Cardiol       Date:  2018-05-17       Impact factor: 1.655

9.  Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia.

Authors:  Emily Ford; Jon Adams; Nicholas Graves
Journal:  BMJ Open       Date:  2012-09-01       Impact factor: 2.692

10.  Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure.

Authors:  Alexander T Sandhu; Jeremy D Goldhaber-Fiebert; Douglas K Owens; Mintu P Turakhia; Daniel W Kaiser; Paul A Heidenreich
Journal:  JACC Heart Fail       Date:  2016-02-10       Impact factor: 12.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.